FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063303670> ?p ?o ?g. }

• W2063303670 endingPage "e72219" @default.
• W2063303670 startingPage "e72219" @default.
• W2063303670 abstract "Introduction Amplification of the ESR1 gene, coding for estrogen receptor alpha, was shown to predict responsiveness to tamoxifen, however its prognostic impact in breast cancer patients has not been thoroughly investigated. Other factors that could contribute to responsiveness to tamoxifen treatment are polymorphisms in ESR1 gene and genes involved in tamoxifen metabolism. The aim of this study was to assess the prognostic role of ESR1 gene dosage in a consecutive group of breast cancer patients and to correlate this feature with clinico-pathological factors. Additionally, ESR1 PvuII, CYP2C19*2 and UGT2B15*2 polymorphisms were analyzed in the tamoxifen-treated subgroup of patients. Materials and Methods Primary tumor samples from 281 stage I-III consecutive breast cancer patients were analyzed for ESR1 gene dosage using real-time PCR with locked nucleic acids hydrolysis probes. In the tamoxifen-treated subgroup of patients, ESR1 PvuII, CYP2C19*2 and UGT2B15*2 polymorphism in leukocytes genomic DNA were analyzed. Results were correlated with clinico-pathological factors and with disease-free survival (DFS) and overall survival (OS). Results ESR1 amplification (with a cut-off level of 2.0) was found in 12% of the entire group of breast cancer patients, and in 18% of the ER-negative subgroup. This feature was associated with decreased DFS both in the entire group (P=0.007) and in the ER-negative subgroup (P=0.03), but not in the tamoxifen-treated patients. Patients with ESR1 PvuII wt/wt genotype and at least one UGT2B15 wt allele had a worse DFS (P=0.03) and showed a trend towards decreased Os (P=0.08) in comparison to patients with ESR1 PvuII wt/vt or vt/vt genotype and UGT2B15 *2/*2 genotype. Conclusions ESR1 amplification can occur in ER-negative tumors and may carry poor prognosis. In the tamoxifen-treated subgroup, poor prognosis was related to the combined presence of ESR1 PvuII wt/wt and UGT2B15wt/wt or wt/*2 genotype." @default.
• W2063303670 created "2016-06-24" @default.
• W2063303670 creator A5004874011 @default.
• W2063303670 creator A5005191627 @default.
• W2063303670 creator A5016791239 @default.
• W2063303670 creator A5021851232 @default.
• W2063303670 creator A5037339560 @default.
• W2063303670 creator A5062328139 @default.
• W2063303670 creator A5066950401 @default.
• W2063303670 date "2013-08-08" @default.
• W2063303670 modified "2023-09-23" @default.
• W2063303670 title "Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients" @default.
• W2063303670 cites W1508838109 @default.
• W2063303670 cites W1550666015 @default.
• W2063303670 cites W1961026612 @default.
• W2063303670 cites W1981241872 @default.
• W2063303670 cites W1982772105 @default.
• W2063303670 cites W1998618966 @default.
• W2063303670 cites W2012407966 @default.
• W2063303670 cites W2013956549 @default.
• W2063303670 cites W2015092588 @default.
• W2063303670 cites W2020016182 @default.
• W2063303670 cites W2027175481 @default.
• W2063303670 cites W2034753152 @default.
• W2063303670 cites W2039986747 @default.
• W2063303670 cites W2044308633 @default.
• W2063303670 cites W2048327703 @default.
• W2063303670 cites W2049308903 @default.
• W2063303670 cites W2051776983 @default.
• W2063303670 cites W2057185405 @default.
• W2063303670 cites W2063345843 @default.
• W2063303670 cites W2082891029 @default.
• W2063303670 cites W2100073637 @default.
• W2063303670 cites W2132893003 @default.
• W2063303670 cites W2138581811 @default.
• W2063303670 cites W2158354974 @default.
• W2063303670 cites W2165378843 @default.
• W2063303670 cites W2170829292 @default.
• W2063303670 cites W2171777347 @default.
• W2063303670 cites W3139657225 @default.
• W2063303670 cites W3142868075 @default.
• W2063303670 cites W4248745773 @default.
• W2063303670 doi "https://doi.org/10.1371/journal.pone.0072219" @default.
• W2063303670 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3738574" @default.
• W2063303670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23951298" @default.
• W2063303670 hasPublicationYear "2013" @default.
• W2063303670 type Work @default.
• W2063303670 sameAs 2063303670 @default.
• W2063303670 citedByCount "20" @default.
• W2063303670 countsByYear W20633036702015 @default.
• W2063303670 countsByYear W20633036702016 @default.
• W2063303670 countsByYear W20633036702018 @default.
• W2063303670 countsByYear W20633036702019 @default.
• W2063303670 countsByYear W20633036702020 @default.
• W2063303670 countsByYear W20633036702021 @default.
• W2063303670 countsByYear W20633036702022 @default.
• W2063303670 countsByYear W20633036702023 @default.
• W2063303670 crossrefType "journal-article" @default.
• W2063303670 hasAuthorship W2063303670A5004874011 @default.
• W2063303670 hasAuthorship W2063303670A5005191627 @default.
• W2063303670 hasAuthorship W2063303670A5016791239 @default.
• W2063303670 hasAuthorship W2063303670A5021851232 @default.
• W2063303670 hasAuthorship W2063303670A5037339560 @default.
• W2063303670 hasAuthorship W2063303670A5062328139 @default.
• W2063303670 hasAuthorship W2063303670A5066950401 @default.
• W2063303670 hasBestOaLocation W20633036701 @default.
• W2063303670 hasConcept C104317684 @default.
• W2063303670 hasConcept C121608353 @default.
• W2063303670 hasConcept C126322002 @default.
• W2063303670 hasConcept C135763542 @default.
• W2063303670 hasConcept C143998085 @default.
• W2063303670 hasConcept C172313692 @default.
• W2063303670 hasConcept C180754005 @default.
• W2063303670 hasConcept C2777164284 @default.
• W2063303670 hasConcept C2777176818 @default.
• W2063303670 hasConcept C33664856 @default.
• W2063303670 hasConcept C502942594 @default.
• W2063303670 hasConcept C530470458 @default.
• W2063303670 hasConcept C54355233 @default.
• W2063303670 hasConcept C63363279 @default.
• W2063303670 hasConcept C71924100 @default.
• W2063303670 hasConcept C84606932 @default.
• W2063303670 hasConcept C86803240 @default.
• W2063303670 hasConceptScore W2063303670C104317684 @default.
• W2063303670 hasConceptScore W2063303670C121608353 @default.
• W2063303670 hasConceptScore W2063303670C126322002 @default.
• W2063303670 hasConceptScore W2063303670C135763542 @default.
• W2063303670 hasConceptScore W2063303670C143998085 @default.
• W2063303670 hasConceptScore W2063303670C172313692 @default.
• W2063303670 hasConceptScore W2063303670C180754005 @default.
• W2063303670 hasConceptScore W2063303670C2777164284 @default.
• W2063303670 hasConceptScore W2063303670C2777176818 @default.
• W2063303670 hasConceptScore W2063303670C33664856 @default.
• W2063303670 hasConceptScore W2063303670C502942594 @default.
• W2063303670 hasConceptScore W2063303670C530470458 @default.
• W2063303670 hasConceptScore W2063303670C54355233 @default.
• W2063303670 hasConceptScore W2063303670C63363279 @default.
• W2063303670 hasConceptScore W2063303670C71924100 @default.

• next